Evidence map›Paper›PMID 30030223›Full record

ArticleApplied and environmental microbiology2018

Response of Secondary Metabolism of Hypogean Actinobacterial Genera to Chemical and Biological Stimuli.

Brett C Covington, Jeffrey M Spraggins, Audrey E Ynigez-Gutierrez, Zachary B Hylton, Brian O Bachmann

Abstract read
In one paragraph

Article in Applied and environmental microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Spirocyclic β-lactone secondary metabolites modulate spliceosome function.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Microbial genomics · 2024
    Article
  12. Review
  13. Article
  14. Article
  15. Small molecule inducers of actinobacteria natural product biosynthesis.Journal of industrial microbiology & biotechnology · 2023
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Brett C CovingtonDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.
Jeffrey M SpragginsDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.
Audrey E Ynigez-GutierrezDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.
Zachary B HyltonDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.
Brian O BachmannDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee, USA brian.bachmann@vanderbilt.edu.

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 1989 to 2026
$19.6M
Training (pp 214-245)P41GM103391 · NIGMS · VANDERBILT UNIVERSITY · PI REYZER, MICHELLE L · 2012 to 2020
$17.7M
VANTAGE:Consolidation to create the Vanderbilt Technologies for Advanced GenomicsG20RR030956 · NCRR · VANDERBILT UNIVERSITY · PI PIETENPOL, JENNIFER A · 2010 to 2010
$8.7M
Chemistry-Biology Interface Training GrantT32GM065086 · NIGMS · VANDERBILT UNIVERSITY · PI BACHMANN, BRIAN O, SULIKOWSKI, GARY ALLEN · 2002 to 2022
$7.0M
New Methodologies for Accelerating Natural Product DiscoveryR01GM092218 · NIGMS · VANDERBILT UNIVERSITY · PI BACHMANN, BRIAN O, MCLEAN, JOHN ALAN · 2010 to 2018
$2.8M
15 Tesla Bruker SolariX FT-ICR mass spectrometerS10OD012359 · OD · VANDERBILT UNIVERSITY · PI CAPRIOLI, RICHARD M · 2012 to 2012
$1.6M
NCI NIH HHS P30 CA068485NCRR NIH HHS G20 RR030956NCRR NIH HHS UL1 RR024975NEI NIH HHS P30 EY008126NIGMS NIH HHS P41 GM103391NIGMS NIH HHS R01 GM092218NIGMS NIH HHS T32 GM065086NIH HHS S10 OD012359
6 · The paper itself

Abstract

Microorganisms within microbial communities respond to environmental challenges by producing biologically active secondary metabolites, yet the majority of these small molecules remain unidentified. We have previously demonstrated that secondary metabolite biosynthesis in actinomycetes can be activated by model environmental chemical and biological stimuli, and metabolites can be identified by comparative metabolomics analyses under different stimulus conditions. Here, we surveyed the secondary metabolite productivity of a group of 20 phylogenetically diverse actinobacteria isolated from hypogean (cave) environments by applying a battery of stimuli consisting of exposure to antibiotics, metals, and mixed microbial culture. Comparative metabolomics was used to reveal secondary metabolite responses from stimuli. These analyses revealed substantial changes in global metabolomic dynamics, with over 30% of metabolomic features increasing more than 10-fold under at least one stimulus condition. Selected features were isolated and identified via nuclear magnetic resonance (NMR), revealing several known secondary metabolite families, including the tetarimycins, aloesaponarins, hypogeamicins, actinomycins, and propeptins. One prioritized metabolite was identified to be a previously unreported aminopolyol polyketide, funisamine, produced by a cave isolate of

Indexed as

Secondary MetabolismActinobacteriaBacterial ProteinsBiological ProductsCavesGenome, BacterialMagnetic Resonance SpectroscopyMetabolomicsMultigene FamilyPhylogenyPolyketidesBacterial ProteinsBiological ProductsPolyketidesactinomycetesantibioticsmetabolomicsmixed culturenatural productssecondary metabolites

Identifiers

PMID30030223
PMCPMC6146984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.